Combined response to commentaries regarding Ivasiy et al. (2025)

This publication has 17 references indexed in Scilit:

• Interpreting extended-release buprenorphine data: The importance of specifying formulations and accurately representing prior evidence
  International Journal of Drug Policy, 2025
• Re: Retention and dropout from sublingual and extended-release buprenorphine treatment: A comparative analysis of data from a nationally representative sample of commercially-insured people with opioid use disorder in the United States
  International Journal of Drug Policy, 2025
• Outpatient Low-Dose Initiation of Buprenorphine for People Using Fentanyl
  JAMA Network Open, 2025
• COVID-19-related flexibility in methadone take-home doses associated with decreased attrition: Report from an opioid treatment program in central Pennsylvania
  Journal of Substance Use and Addiction Treatment, 2023
• Buprenorphine Dose and Time to Discontinuation Among Patients With Opioid Use Disorder in the Era of Fentanyl
  JAMA Network Open, 2023
• Economic Evaluation of Extended-Release Buprenorphine for Persons With Opioid Use Disorder
  JAMA Network Open, 2023
• Characterizing initiation, use, and discontinuation of extended-release buprenorphine in a nationally representative United States commercially insured cohort
  Drug and Alcohol Dependence, 2021
• Short communication: Systematic review on effectiveness of micro-induction approaches to buprenorphine initiation
  Addictive Behaviors, 2021
• Comparative Effectiveness of Different Treatment Pathways for Opioid Use Disorder
  JAMA Network Open, 2020
• Weekly and Monthly Subcutaneous Buprenorphine Depot Formulations vs Daily Sublingual Buprenorphine With Naloxone for Treatment of Opioid Use Disorder
  JAMA Internal Medicine, 2018